Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more
Shenzhen Lifotronic Technology Co (688389) - Net Assets
Latest net assets as of September 2025: CN¥2.10 Billion CNY
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has net assets worth CN¥2.10 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.65 Billion) and total liabilities (CN¥549.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.10 Billion |
| % of Total Assets | 79.23% |
| Annual Growth Rate | 23.82% |
| 5-Year Change | 79.21% |
| 10-Year Change | N/A |
| Growth Volatility | 19.28 |
Shenzhen Lifotronic Technology Co - Net Assets Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shenzhen Lifotronic Technology Co (2016–2024)
The table below shows the annual net assets of Shenzhen Lifotronic Technology Co from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.05 Billion | +14.01% |
| 2023-12-31 | CN¥1.80 Billion | +24.53% |
| 2022-12-31 | CN¥1.44 Billion | +14.75% |
| 2021-12-31 | CN¥1.26 Billion | +10.00% |
| 2020-12-31 | CN¥1.14 Billion | +8.95% |
| 2019-12-31 | CN¥1.05 Billion | +57.04% |
| 2018-12-31 | CN¥668.39 Million | +13.82% |
| 2017-12-31 | CN¥587.25 Million | +58.36% |
| 2016-12-31 | CN¥370.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Lifotronic Technology Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1843.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥879.96 Million | 42.90% |
| Common Stock | CN¥428.49 Million | 20.89% |
| Other Comprehensive Income | CN¥132.27 Million | 6.45% |
| Other Components | CN¥610.24 Million | 29.75% |
| Total Equity | CN¥2.05 Billion | 100.00% |
Shenzhen Lifotronic Technology Co Competitors by Market Cap
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
$370.62 Million |
|
Hangzhou Star Shuaier Electric Appliance Co Ltd
SHE:002860
|
$370.64 Million |
|
GSR III Acquisition Corp. Unit
NASDAQ:GSRTU
|
$370.68 Million |
|
Veradigm Inc.
NASDAQ:MDRX
|
$370.81 Million |
|
Yuhuan CNC Machine Tool Co Ltd
SHE:002903
|
$370.48 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
$370.38 Million |
|
Titan International Inc
NYSE:TWI
|
$370.35 Million |
|
JSL Construction & Development Co Ltd
TW:2540
|
$370.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Lifotronic Technology Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,796,746,247 to 2,050,964,593, a change of 254,218,346 (14.1%).
- Net income of 345,391,536 contributed positively to equity growth.
- Dividend payments of 125,055,408 reduced retained earnings.
- Other comprehensive income increased equity by 43,904,471.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥345.39 Million | +16.84% |
| Dividends Paid | CN¥125.06 Million | -6.1% |
| Other Comprehensive Income | CN¥43.90 Million | +2.14% |
| Other Changes | CN¥-10.02 Million | -0.49% |
| Total Change | CN¥- | 14.15% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Lifotronic Technology Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.14x to 2.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.01 | CN¥13.31 | x |
| 2017-12-31 | CN¥1.60 | CN¥13.31 | x |
| 2018-12-31 | CN¥1.73 | CN¥13.31 | x |
| 2019-12-31 | CN¥2.49 | CN¥13.31 | x |
| 2020-12-31 | CN¥2.71 | CN¥13.31 | x |
| 2021-12-31 | CN¥2.97 | CN¥13.31 | x |
| 2022-12-31 | CN¥3.41 | CN¥13.31 | x |
| 2023-12-31 | CN¥4.21 | CN¥13.31 | x |
| 2024-12-31 | CN¥4.78 | CN¥13.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Lifotronic Technology Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.84%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.09%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.41x
- Recent ROE (16.84%) is above the historical average (12.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.66% | 5.66% | 0.35x | 1.34x | CN¥-27.20 Million |
| 2017 | 8.10% | 18.97% | 0.35x | 1.21x | CN¥-11.14 Million |
| 2018 | 12.14% | 25.09% | 0.40x | 1.21x | CN¥14.30 Million |
| 2019 | 9.58% | 23.79% | 0.36x | 1.12x | CN¥-4.41 Million |
| 2020 | 12.59% | 25.99% | 0.43x | 1.13x | CN¥29.65 Million |
| 2021 | 15.16% | 24.46% | 0.53x | 1.17x | CN¥64.80 Million |
| 2022 | 17.47% | 25.58% | 0.54x | 1.26x | CN¥107.50 Million |
| 2023 | 18.29% | 28.68% | 0.49x | 1.30x | CN¥148.91 Million |
| 2024 | 16.84% | 30.09% | 0.40x | 1.41x | CN¥140.30 Million |
Industry Comparison
This section compares Shenzhen Lifotronic Technology Co's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Lifotronic Technology Co (688389) | CN¥2.10 Billion | 2.66% | 0.26x | $370.56 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |